Medarex, Inc. To Announce 2005 Fourth Quarter And Year-End Financial Results On March 6, 2006

PRINCETON, N.J., March 2 /PRNewswire-FirstCall/ -- Medarex, Inc. is scheduled to announce its 2005 fourth quarter and year-end results on Monday, March 6, 2006 by press release after the financial markets close. Following the release, Medarex's management expects to host a conference call and live audio webcast at 4:30 PM Eastern Time to discuss the financial results and other business matters. To access the call live, please dial 800-322-2803 within the U.S. or 617-614-4925 outside of the U.S. and enter passcode 20239831. The call will also be webcast live via the Internet at www.medarex.com.

A replay of the webcast will be available on the Webcasts page in the Investor Relations section of Medarex's website at www.medarex.com and will be archived for 14 days following the webcast. An audio replay of the conference call will be available until midnight Eastern Time, March 20, 2006. To access the audio archive, please dial 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and enter passcode 61872385.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Thirty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with four of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

Medarex, Inc.

CONTACT: Christian S. Schade, Senior VP and CFO, +1-609-430-2880, or LauraS. Choi, Investor Relations, +1-609-430-2880, x2216, or Jean Mantuano,Corporate Communications (media), +1-609-430-2880, x2221, all of Medarex

Back to news